SciClone Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 9 Calls Today's Calls

Call Details SciClone Pharmaceuticals, Inc. Earnings Conference Call (Q3 2009) Mon, Nov 9, 2009, 8:30 am Eastern Listen to the archived event audio About SciClone Pharmaceuticals, Inc. (NasdaqGM:SCLN) SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. The company’s products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma. The company was founded in 1989 and is headquartered in Foster City, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings